AlphAIAlphAI — Financial news for AI agents
investing.com$TXG

10X Genomics earnings beat by $0.11, revenue topped estimates

10X Genomics (TXG) reported Q3 EPS of -$0.15, beating estimates by $0.11, with revenue of $150.66M, exceeding expectations. The company forecasted FY 2026 revenue of $625M-$635M, higher than analyst consensus. TXG's stock is up 11.59% in 3 months and 346.62% in 12 months.

Original reporting
investing.com
Published Nov 5, 2026, 10:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TXG
Bullish
high confidence
Mentioned
$TXG
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TXGBullishHigh
01

Why it matters

The earnings beat and FY guidance raise expectations for revenue growth, likely supporting the stock in the near term.

02

Market read

Fresh earnings data provides a clear catalyst for TXG and may influence peer valuations.

03

What to watch

Potential headwinds from competitive pressure and upcoming product pipeline milestones.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

10X Genomics is a leading provider of genomic analysis tools; its earnings are closely watched by biotech investors.

Company-level read

Ticker impact

$TXGBullishHigh confidence
Context

TXG reported Q3 EPS beat and revenue above estimates, providing fresh earnings data.

Expected impact

potential upward pressure as investors price in the beat and guidance lift

Evidence & confidence

The beat and raised FY guidance are new, material information for a mid‑cap biotech.

Market effects

Sector

Positive earnings may lift the broader genomics and biotech sector.

Regional

Limited to US markets where TXG trades.

Global

Modest; primarily affects investors tracking US biotech stocks.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face profit‑taking.

Key entities

  • company
    10X Genomics

    NASDAQ‑listed genomics technology firm.

Read at source← All news

Story10x Genomics reports Q3 2026 results and lifts full‑year revenue outlook

Also covered by

5 outlets

Related articles

$TXGMedAI 8/10

What 10x Genomics (TXG) Said on Its Q3 Earnings Call

10x Genomics (TXG) reported Q3 earnings, with consumables revenue up 5% YoY, driven by spatial products. Instrument revenue fell 43%, attributed to fewer units sold. Gross margin rose to 75% but is expected to decline in Q4 due to Atera instrument shipments. The company ended the quarter with $576M in cash. TXG also announced new software and clinical initiatives.

finance.yahoo.com
$TXGMed

Stifel raises 10X Genomics stock price target on Atera outlook

Stifel raised 10X Genomics' (TXG) price target to $68 from $50, citing strong Q3 results and increased Atera placement expectations. The stock has risen 347% over the past year, trading at $58.06. Analysts predict profitability this year with an EPS of $0.10, though the stock appears overvalued. Revenue was $150.66M, beating estimates, but margins are expected to decline due to Atera shipments.

investing.com